MANKIND vs PGHL: Stock Comparison

Mankind Pharma Limited vs Procter & Gamble Health Limited

Live data: 22 July 2026, 3:03 PM IST • Source: NSE and company filings

Mankind Pharma Limited is the larger company by market capitalisation. Procter & Gamble Health Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Mankind Pharma Limited and Procter & Gamble Health Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MANKIND is more favourable on 1 of 13 scored metrics and PGHL on 12These counts are context-free and are not an overall rating.

Key Differences

Market Cap
MANKIND is the larger company
₹1.05 L Cr vs ₹11,172 Cr
P/E Ratio
PGHL has a lower P/E
34.28x vs 55.54x
P/B Ratio
MANKIND has a lower P/B
6.52x vs 21.36x
EPS
PGHL has higher earnings per share
₹196.64 vs ₹46.34
Dividend Yield
PGHL has a higher dividend yield
2.34% vs 0.04%
Revenue Growth (TTM YoY)
PGHL has faster revenue growth
19.1% vs 11.8%
EPS Growth (TTM YoY)
PGHL has faster EPS growth
54.6% vs 31.7%
Qtr Sales Growth
PGHL has stronger quarterly sales growth
19.1% vs 11.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMANKINDPGHL
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMANKINDPGHL
Live Price₹2,546.6₹6,737
Day Change-1.28%-0.63%
Volume2.67 L4,611
52-Week High₹2,690₹6,975
52-Week Low₹1,909.7₹4,707
Distance from 52W High-5.33%-3.41%

Valuation

MetricMANKINDPGHL
Market Cap₹1.05 L Cr₹11,172 Cr
P/E Ratio55.54x34.28x
P/B Ratio6.52x21.36x
EPS₹46.34₹196.64
Book Value₹395.2₹316.01
Dividend Yield0.04%2.34%

Growth

MetricMANKINDPGHL
Revenue Growth (TTM YoY)11.8%19.1%
EPS Growth (TTM YoY)31.7%54.6%
Qtr Sales Growth11.8%19.1%
Qtr Profit Growth34.2%54.6%

Profitability & Leverage

MetricMANKINDPGHL
ROE13.1%61.6%
ROCE13.5%83.5%
Net Margin13.34%23.22%
Operating Margin25.3%32.4%
Debt to Equity0.39x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricMANKINDPGHL
Promoter Holding72.66%0%
FII Holding10.24% 1.1 pp6.33% 0.13 pp
DII Holding14.46% 1.21 pp12.44% 1.23 pp
Public Holding2.64% 0.11 pp29.42% 1.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Mankind Pharma Limited and Procter & Gamble Health Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.